| pubmed-article:18032038 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18032038 | lifeskim:mentions | umls-concept:C0041942 | lld:lifeskim |
| pubmed-article:18032038 | lifeskim:mentions | umls-concept:C1332822 | lld:lifeskim |
| pubmed-article:18032038 | lifeskim:mentions | umls-concept:C1527148 | lld:lifeskim |
| pubmed-article:18032038 | lifeskim:mentions | umls-concept:C0243076 | lld:lifeskim |
| pubmed-article:18032038 | lifeskim:mentions | umls-concept:C0243072 | lld:lifeskim |
| pubmed-article:18032038 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:18032038 | pubmed:dateCreated | 2008-1-9 | lld:pubmed |
| pubmed-article:18032038 | pubmed:abstractText | The optimization of a series of 1-aryl-3-piperidinyl urea derivatives is described in which incorporation of tropenyl and homotropenyl moieties has led to significant improvements in activity and drug-like properties. Replacement of the central piperidine with an exo-tropanyl unit led to the identification of compound 15 which provides a combination of excellent potency against human and murine receptors, drug-like properties and pharmacokinetics, thus providing a valuable tool for the evaluation of CXCR3 antagonists in models of human disease. | lld:pubmed |
| pubmed-article:18032038 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18032038 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18032038 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18032038 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18032038 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18032038 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18032038 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18032038 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18032038 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18032038 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:18032038 | pubmed:issn | 1464-3405 | lld:pubmed |
| pubmed-article:18032038 | pubmed:author | pubmed-author:JoplingLouise... | lld:pubmed |
| pubmed-article:18032038 | pubmed:author | pubmed-author:OwenDavid ADA | lld:pubmed |
| pubmed-article:18032038 | pubmed:author | pubmed-author:BirchHelen... | lld:pubmed |
| pubmed-article:18032038 | pubmed:author | pubmed-author:KnightRoland... | lld:pubmed |
| pubmed-article:18032038 | pubmed:author | pubmed-author:WilliamsSophi... | lld:pubmed |
| pubmed-article:18032038 | pubmed:author | pubmed-author:WatsonRobert... | lld:pubmed |
| pubmed-article:18032038 | pubmed:author | pubmed-author:AllenDaniel... | lld:pubmed |
| pubmed-article:18032038 | pubmed:author | pubmed-author:ChapmanGayle... | lld:pubmed |
| pubmed-article:18032038 | pubmed:author | pubmed-author:MeissnerJohan... | lld:pubmed |
| pubmed-article:18032038 | pubmed:author | pubmed-author:ThomasElizabe... | lld:pubmed |
| pubmed-article:18032038 | pubmed:author | pubmed-author:GalvinFrances... | lld:pubmed |
| pubmed-article:18032038 | pubmed:author | pubmed-author:MeierDoricaD | lld:pubmed |
| pubmed-article:18032038 | pubmed:author | pubmed-author:OliverKathryn... | lld:pubmed |
| pubmed-article:18032038 | pubmed:author | pubmed-author:TremayneNeilN | lld:pubmed |
| pubmed-article:18032038 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18032038 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:18032038 | pubmed:volume | 18 | lld:pubmed |
| pubmed-article:18032038 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18032038 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18032038 | pubmed:pagination | 147-51 | lld:pubmed |
| pubmed-article:18032038 | pubmed:meshHeading | pubmed-meshheading:18032038... | lld:pubmed |
| pubmed-article:18032038 | pubmed:meshHeading | pubmed-meshheading:18032038... | lld:pubmed |
| pubmed-article:18032038 | pubmed:meshHeading | pubmed-meshheading:18032038... | lld:pubmed |
| pubmed-article:18032038 | pubmed:meshHeading | pubmed-meshheading:18032038... | lld:pubmed |
| pubmed-article:18032038 | pubmed:meshHeading | pubmed-meshheading:18032038... | lld:pubmed |
| pubmed-article:18032038 | pubmed:meshHeading | pubmed-meshheading:18032038... | lld:pubmed |
| pubmed-article:18032038 | pubmed:meshHeading | pubmed-meshheading:18032038... | lld:pubmed |
| pubmed-article:18032038 | pubmed:meshHeading | pubmed-meshheading:18032038... | lld:pubmed |
| pubmed-article:18032038 | pubmed:meshHeading | pubmed-meshheading:18032038... | lld:pubmed |
| pubmed-article:18032038 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18032038 | pubmed:articleTitle | Development of CXCR3 antagonists. Part 3: Tropenyl and homotropenyl-piperidine urea derivatives. | lld:pubmed |
| pubmed-article:18032038 | pubmed:affiliation | UCB Inflammation Discovery, Granta Park, Great Abington, Cambridge CB21 6GS, United Kingdom. bob.watson@ucb-group.com | lld:pubmed |
| pubmed-article:18032038 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:18032038 | lld:chembl |
